Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6609161 | 0.91 | TACR2 (0.40) | TACR2MEN1BLMKMT2ALMNA | |
| SCHEMBL6599105 | 0.90 | TACR2 (0.51) | TACR2KMT2ALMNAMAPT | |
| SCHEMBL6595002 | 0.89 | CHRM1 (0.49) | TACR2 | |
| SCHEMBL6597801 | 0.89 | TACR2 (0.45) | TACR2MEN1BLMKMT2A | |
| SCHEMBL6599334 | 0.87 | TACR2 (0.49) | TACR2 | |
| SCHEMBL6607357 | 0.87 | LMNA (0.46) | TACR2MEN1BLMKMT2ALMNA | |
| SCHEMBL6600856 | 0.86 | TACR2 (0.39) | TACR2MEN1BLMKMT2ALMNA | |
| SCHEMBL6595639 | 0.86 | TACR2 (0.47) | TACR2 | |
| SCHEMBL6598517 | 0.85 | TACR2 (0.49) | TACR2 | |
| SCHEMBL6596599 | 0.85 | CHRM1 (0.47) | TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0888338-B1 | NOVEL SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL) 1,4]DIAZEPAN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | AVENTIS PHARMA INC (US) | 2004-11-17 | — | — | EP | disclosed |